WEST HAVEN, CT--(Marketwired - December 23, 2013) -
NanoViricides, Inc. (NYSE MKT: NNVC
) is a development stage company that is creating special purpose nanomaterials to destroy viruses in and on the body. The Company today announced that Michael Yorba of Clear Channel's Business Talk Radio Show, The Traders Network, interviewed CEO Dr. Eugene Seymour live on December 19, 2013.
In this very informative one on one interview, Dr Seymour was asked about their platform technology to rapidly create anti-viral drugs and how it related to HIV/AIDS and other viral diseases. He explained the construction and function of their line-up of drugs all work on the same basic principle. A nanomicelle that is a 20 nanometer polymeric-based structure attached to a "mimic" of the receptor protein that sits on the host cell that is then used to lure the virus to the cell. For example; Influenza is a virus that causes the illness known at "flu." If you can at least control, or better yet, destroy the virus in the bloodstream, you can reverse the symptoms of the illness, allowing the patient to recover quickly.
He went on to explain that viruses only grow in cells and thus in order for the virus to reproduce, it must attach to and enter their unique host cell. In an effort to "fool" the virus into attaching to our nanoviricide, we place a "mimic" of the receptor protein found on the surface of the host cell of that particular virus on our nanomicelle, creating the nanoviricide. The nanoviricide then opens up, encapsulates and then destroys the virus. Once you understand this, you understand how all our drugs work.
Yorba asked, "How is your drug administered?"
For influenza, we plan an intravenous route of administration for seriously or critically ill hospitalized patients. For outpatients, we're planning to use a single dose oral liquid. For herpes of the eye, eye drops and for genital herpes, we plan to use an ointment. For HIV/AIDS, initially an intravenous loading dose.
At this point Dr. Seymour reminded listeners that they still need to do human trials, and would have much more information after those trials have been completed.
NanoViricides, Inc.'s achievements this past year was, receiving orphan drug designation from the European Union and the US FDA for DengueCide, their drug for Dengue Hemorrhagic Fever, and Dengue. Also starting construction of their high tech, state of the art nano-medicine anti-viral drug manufacturing plant, the only one in the US and possibly the entire world. Next year's plans include: finishing the plant, completing toxicology studies and submitting paperwork to FDA, while awaiting for permission to start human trials.
Listen to the entire live archive Clear Channel Interview, detail below.
Archive Interview Link: http://www.yorbamedia.com/images/stories/audio/TN121913SEG1.mp3
Network: Clear Channel
Station: DFW 1190AM
Host: Michael Yorba
Michael Yorba host of Clear Channel's The Traders Network Show later stated, "What NanoViricides is doing is simply a game changer! We look forward to having Dr. Seymour back for a part-2 interview in 2014. We are expecting big things from this company."
About Clear Channel Clear Channel Media and Entertainment's more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country. DFW1190AM.com Dallas-Ft. Worth, TX (www.clearchannel.com).
About Michael Yorba Michael Yorba -- featured host of Clear Channels DFW 1190AM in Dallas-Ft.Worth. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on internet television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex. www.yorbamedia.com.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
A www.1800PublicRelations.com PR Event